Related Experiment Video

Updated: Jun 1, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

Presumed bilateral branch retinal vein occlusions secondary to antiepileptic agents

Rumana N Hussain1, Somnath Banerjee

  • 1Leicester Royal Infirmary, Leicester, UK.

Clinical Ophthalmology (Auckland, N.Z.)
|June 10, 2011
PubMed

Insights

A man with epilepsy developed vision problems due to high homocysteine levels. This case highlights a potential link between antiepileptic drugs, elevated homocysteine, and retinal vascular events.

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Neurology

Background:

  • Branch retinal vein occlusions (BRVO) are a significant cause of vision loss.
  • Elevated plasma homocysteine is a known risk factor for vascular disease.
  • Antiepileptic drugs can affect folate metabolism and homocysteine levels.

Observation:

  • A 61-year-old male patient presented with bilateral BRVO.
  • Initial blood tests were normal, but further investigation revealed hyperhomocysteinemia.
  • The patient had a history of refractory epilepsy treated with antiepileptic medications.

Findings:

  • The patient's hyperhomocysteinemia was linked to his long-term antiepileptic drug use.
  • The elevated homocysteine level was implicated as the cause of the bilateral BRVO.
  • This case demonstrates a previously unestablished level of homocysteine elevation causing retinal vascular events.

Implications:

  • This case suggests a potential causal relationship between antiepileptic drug-induced hyperhomocysteinemia and BRVO.
  • Ophthalmologists should consider homocysteine levels in patients with unexplained BRVO, especially those with epilepsy.
  • Further research is warranted to explore the link between antiepileptic drugs, homocysteine, and retinal vascular occlusive events.

Keywords:
branch vein occlusionshomocysteine

More Related Videos

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility07:35

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

Published on: April 21, 2022

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...